Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population: BRIEF COMMUNICATION

Tissue Antigens

Volumn 74, Issue 3, 2009, Pages 244-247

  Fedetz, M ^a   Ndagire, D ^a   Fernandez, O ^b   Leyva, L ^b   Guerrero, M ^b   Arnal, C ^c   Lucas, M ^d   Izquierdo, G ^d   Delgado, C ^e   Alcina, A ^a   Matesanz, F ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e Centro Regional de Transfusión Sanguínea Granada Almería   (Spain)

Author keywords

4q27; Case control association study; Interleukin 2; Interleukin 21; Multiple sclerosis; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 21;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CHROMOSOME 4Q; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ALLELES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKIN-2; INTERLEUKINS; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION GROUPS; PROBABILITY; SPAIN;

EID: 68249094435     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01298.x     Document Type: Article

References (33)

1. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007 : 39 : 857 64.
2. van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007 : 39 : 827 9.
3. Liu Y, Helms C, Liao W et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008 : 4 : e1000041.
4. Matesanz F, Fedetz M, Collado-Romero M et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol 2001 : 119 : 101 5.
5. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002 : 53 : 285 302.
6. Dyment DA, Ebers GC, Sadovnic AD. Genetics of multiple sclerosis. Lancet Neurol 2004 : 3 : 104 10.
7. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006 : 212 : 203 16.
8. Nielsen NM, Westergaard T, Frisch M et al. Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch Neurol 2006 : 3 : 1001 4.
9. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005 : 129 : 819 26.
10. Corporaal S, Bijl M, Kallenberg CG. Familial occurrence of autoimmune diseases and autoantibodies in a Caucasian population of patients with systemic lupus erythematosus. Clin Rheumatol 2002 : 21 : 108 13.
11. Ramagopalan SV, Dyment DA, Valdar W et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007 : 6 : 604 10.
12. Marrie RA. Autoimmune disease and multiple sclerosis: methods, methods, methods. Lancet Neurol 2007 : 6 : 575 76.
13. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008 : 26 : 453 79.
14. Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 2007 : 13 : 6926 32.
15. + regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol 2008 : 67 : 37 46.
16. Clough LE, Wang CJ, Schmidt EM et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 2008 : 180 : 5393 401.
17. Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007 : 178 : 732 39.
18. Asano K, Ikegami H, Fujisawa T et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007 : 68 : 384 91.
19. Sawalha AH, Kaufman KM, Kelly JA et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008 : 67 : 458 61.
20. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Intern Med J 1983 : 13 : 227 31.
21. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 : 46 : 907 11.
22. de Bakker PI, Burtt NP, Graham RR et al. Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet 2006 : 38 : 1298 303.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005 : 21 : 263 65.
24. Zhernakova A, Alizadeh BZ, Bevova M et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007 : 81 : 1284 88.
25. Ramagopalan SV, Deluca GC, Degenhardt A, Ebers GC. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008 : 201-202 : 183 99.
26. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008 : 14 : 314 24.
27. Hoffmann SC, Stanley EM, Cox D et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001 : 72 : 1444 50.
28. Matesanz F, Fedetz M, Leyva L, Delgado C, Fernández O, Alcina A. Effects of the multiple sclerosis associated-330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol 2004 : 148 : 212 17.
29. Waithman J, Gebhardt T, Davey GM, Heath WR, Carbone FR. Enhanced IL-2 signaling can convert self-specific T cell response from tolerance to autoimmunity. J Immunol 2008 : 180 : 5789 93.
30. del Rio R, Noubade R, Subramanian M et al. SNPs upstream of the minimal promoter control IL-2 expression and are candidates for the autoimmune disease-susceptibility locus Aod2/Idd3/Eae3. Genes Immun 2008 : 9 : 115 21.
31. Brandenburg S, Takahashi T, de la Rosa M et al. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol 2008 : 38 : 1643 53.
32. Laurence A, Tato CM, Davidson TS et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007 : 26 : 371 81.
33. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007 : 8 : 913 19 (Review).